Varenicline Pfizer New Zealand - English - Medsafe (Medicines Safety Authority)

varenicline pfizer

pfizer new zealand limited - varenicline tartrate 1.71mg equivalent to 1 mg varenicline;  ;   - film coated tablet - 1 mg - active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

Varenicline Pfizer 0.5 mg and 1 mg tablets New Zealand - English - Medsafe (Medicines Safety Authority)

varenicline pfizer 0.5 mg and 1 mg tablets

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;  ; varenicline tartrate 1.71mg equivalent to 1 mg varenicline - combination - 0.5 mg and 1 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

Premia 2.5 Continuous New Zealand - English - Medsafe (Medicines Safety Authority)

premia 2.5 continuous

pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.);  ; medroxyprogesterone acetate 2.6mg (includes 4% overage.); conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.); medroxyprogesterone acetate 2.6mg (includes 4% overage.) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.)   medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.) medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide  

Premia 5 Continuous New Zealand - English - Medsafe (Medicines Safety Authority)

premia 5 continuous

pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.);  ; medroxyprogesterone acetate 5mg (includes 4% overage); conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.); medroxyprogesterone acetate 5mg (includes 4% overage) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.)   medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.) medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate indigo carmine lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide  

Duavive New Zealand - English - Medsafe (Medicines Safety Authority)

duavive

pfizer new zealand limited - bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat;  ; conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core);   - modified release tablet - 0.45mg/20mg - active: bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat   conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core)   excipient: ascorbic acid hyprolose hypromellose     isopropyl alcohol lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode black ns-78-17821 opadry pink 03b14899 opaglos clear 98z19173 purified water     sucrose   sucrose palmitate - duavive is indicated for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. the experience treating women older than 65 years is limited.

Tygacil New Zealand - English - Medsafe (Medicines Safety Authority)

tygacil

pfizer new zealand limited - tigecycline 50mg (plus a 6% overage to compensate for losses during reconsitution and withdrawal);   - powder for injection - 50 mg - active: tigecycline 50mg (plus a 6% overage to compensate for losses during reconsitution and withdrawal)   excipient: lactose monohydrate - tygacil is indicated for the treatment of the following infections in adults: · complicated skin and skin structure infections, including those with methicillin-resistant staphylococcus aureus (mrsa), where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents. · complicated intra-abdominal infections, where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents.

Edronax New Zealand - English - Medsafe (Medicines Safety Authority)

edronax

pfizer new zealand limited - reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base - tablet - 4 mg - active: reboxetine mesilate 5.224mg equivalent to 4 mg reboxetine free base excipient: calcium hydrogen phosphate dihydrate crospovidone hydrated silica magnesium stearate powdered cellulose

Lincocin New Zealand - English - Medsafe (Medicines Safety Authority)

lincocin

pfizer new zealand limited - lincomycin hydrochloride monohydrate 340.26 mg/ml equivalent to lincomycin 300 mg/ml - solution for injection - 300 mg/ml - active: lincomycin hydrochloride monohydrate 340.26 mg/ml equivalent to lincomycin 300 mg/ml excipient: benzyl alcohol water for injection

Heparin Sodium (Pfizer) New Zealand - English - Medsafe (Medicines Safety Authority)

heparin sodium (pfizer)

pfizer new zealand limited - heparin sodium 5000 iu/ml;   - solution for injection - 25000 iu/5ml - active: heparin sodium 5000 iu/ml   excipient: hydrochloric acid sodium hydroxide water for injection

Heparin Sodium (Pfizer) New Zealand - English - Medsafe (Medicines Safety Authority)

heparin sodium (pfizer)

pfizer new zealand limited - heparin sodium 1000 iu/ml;   - solution for injection - 5000 iu/5ml - active: heparin sodium 1000 iu/ml   excipient: hydrochloric acid sodium hydroxide water for injection